Introduction
In patients with prostate cancer, disease progression can have serious clinical consequences, such as painful bone metastases, spinal cord compression, pathological fractures and urinary dysfunction. 1 Patients and their carers/family members can suffer depression and anxiety at signs of advancing disease, which impacts on their quality of life. 2 Furthermore, metastatic and prostate-specific antigen (PSA) progression pose a significant economic burden. 3, 4 The ongoing bicalutamide ('Casodex') Early Prostate Cancer (EPC) programme is evaluating whether the addition of bicalutamide 150 mg/ day to standard care can reduce the risk of disease progression as well as improve overall survival in patients with localised (T1-2, N0 or Nx, M0) or locally advanced prostate cancer (T3-4, any N, M0 or any T, N þ , M0). This programme, the largest prostate cancer study to date, consists of three randomised, doubleblind, placebo-controlled trials (Trial 23, 24 and 25). 5, 6 Although the three trials in the EPC programme were prospectively designed and powered for a combined analysis, it is important to consider each trial separately as well as in the context of the overall results. In Trial 25, conducted in Scandinavia, over three-quarters of patients were untreated before entry; therefore, findings essentially reflect those of immediate hormonal therapy vs watchful waiting. 7 Trial 23, a North American trial, is evaluating the benefit of early antiandrogen therapy, predominantly in patients with localised prostate cancer undergoing radical prostatectomy.
This manuscript reports the results from Trial 24, which is being conducted primarily in Europe. The results from the first planned analysis of Trial 24, performed at 2.6 y median follow-up, showed that bicalutamide significantly improved objective progression-free survival (PFS), irrespective of primary therapy and disease stage. The tolerability profile was closely linked to the pharmacology of bicalutamide, with gynaecomastia and breast pain the most frequently reported adverse events (mild to moderate in most cases). 8 Trial 24 is ongoing and this article reports the findings of the second planned analysis of this Trial, performed at 5.1 y median follow-up.
Methods
The methods for Trial 24 have been previously described 8 and are presented here in brief.
Trial design
Trial 24, a randomised, double-blind, placebo-controlled trial, recruited 3603 patients between September 1995 and July 1998 from 191 centres in non-Scandinavian Europe (n ¼ 2925), South Africa (n ¼ 394), Israel (n ¼ 193), Mexico (n ¼ 77) and Australia (n ¼ 14). Men aged X18 y diagnosed with clinically or pathologically confirmed nonmetastatic prostate cancer (T1b-4, any N, M0), who gave written informed consent, were included in the trial. These patients would have otherwise not received hormonal therapy following standard care.
Following standard care, patients included in the trial were randomised 1 : 1 to receive either bicalutamide 150 mg or placebo once daily. For radical prostatectomy and radiotherapy patients, it was recommended that randomised treatment should continue until objective disease progression or up to a maximum of 5 y. In watchful waiting patients, randomised therapy was recommended until objective disease progression with no maximum duration. Alternative therapy upon disease progression was initiated at the investigators' discretion. Patients are being followed for objective progression and death.
The trial was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines, and with Independent Ethics Committee approval at each centre.
Assessments and end points
Assessments for patients receiving randomised treatment were made at 12-weekly intervals for local and regional disease, distant metastases, clinical symptoms, PSA level, liver biochemistry and other clinical laboratory parameters. Patients withdrawn from therapy were followed every 24 weeks until death.
The primary end points in Trial 24 were objective PFS and tolerability. Objective PFS was defined as the time from randomisation to the earliest sign of objective progression (confirmed by bone scan, computed tomography, ultrasound or magnetic resonance imaging scan, or histological evidence of distant metastases), or to death from any cause without progression. Tolerability was assessed by examining the number of patients who reported adverse events, classified using the Coding Symbols for Thesaurus of Adverse Reaction Terms (COSTART) system. Secondary end points were overall survival (time from randomisation to death) and PSA PFS (time from randomisation to the earliest point of PSA doubling, objective progression or death). Serum PSA levels were measured every 12 weeks using the Hybritech assay (Hybritech Inc., San Diego, USA). Patients with baseline PSA levels below the limit of quantification (1.0 ng/ml) were considered to have reached PSA doubling if their PSA level increased to X2 ng/ml.
Statistical analyses
The timing of this second preplanned analysis of Trial 24 was based on the accrual of sufficient deaths across the whole EPC programme to allow detection of a 15% reduction in the overall mortality rate in the overall population with 80% power and 5% two-sided significance. It was estimated that by 31 December 2002 (4.5 y minimum follow-up), the required number of events (1200) across the whole EPC programme would have occurred. The predicted statistical estimates were met at the time of the second analysis (4.5 y minimum followup) as 1236 patients had died across the whole programme. 6 The statistical methods used have been described previously. 8 Efficacy data for the overall Trial 24 population were analysed on an intent-to-treat basis using a Cox proportional hazards regression model, which estimates the hazard ratio (HR) for the reduction in the risk of an event for bicalutamide relative to standard care alone. As part of the Statistical Analysis Plan, a statistical test was performed that examined whether the relative effect of bicalutamide on overall survival was dependent on certain prespecified baseline prognostic factors, such as baseline PSA level, Gleason score and disease stage.
Results

Patients
Of the 3603 men recruited into Trial 24, approximately two-thirds had received surgery or radiotherapy and Bicalutamide 150 mg in addition to standard care M Wirth et al approximately one-third had received no primary treatment. A total of 1798 patients were randomised to receive bicalutamide and 1805 patients were randomised to receive placebo. The two treatment groups were well balanced in terms of patient demography and baseline disease characteristics (Table 1) .
Following the first analysis of the full EPC programme data set, 5 the study blind was broken due to a significantly lower risk of objective disease progression with the addition of bicalutamide to standard care compared with placebo. Investigators and patients were informed of the results and patients had the option of breaking their blind and switching to bicalutamide as open-label therapy. A total of 12% of patients broke their blind in Trial 24; 300 patients (8.3%) were still receiving randomised therapy when the blind was broken, of which 214 changed to open-label bicalutamide (94 had been previously randomised to bicalutamide and 120 to placebo). All patients continue to be followed for progression and survival.
Efficacy
The median follow-up at this analysis was 5.1 y. The median duration of randomised therapy according to underlying standard care is given in Table 1 .
Overall survival At the time of analysis, 17.8% (320/ 1798) of patients randomised to bicalutamide and 17.5% (316/1805) randomised to placebo had died. There was no significant difference in overall survival between the two treatment groups across the Trial 24 population (HR 1.03; 95% confidence intervals [CI] 0.88, 1.20; P ¼ 0.746) (Figure 1) . The statistical interaction test to determine Figure 2 ). A significant difference in favour of bicalutamide treatment was seen for both the subgroup of patients randomised to adjuvant therapy and the subgroup of patients undergoing watchful waiting ( 
Safety and tolerability
A total of 3585 patients were included in the safety population (1790 randomised to bicalutamide and 1795 randomised to placebo). In all, 18 patients who did not receive randomised therapy were excluded from the safety analyses.
Adverse events The tolerability of bicalutamide was consistent with that observed at the first analysis of Trial 24 8 and the combined analysis. 6 The most common adverse events associated with bicalutamide treatment were gynaecomastia (67.9%) and breast pain (66.3%) ( Table 3 ) and were of mild to moderate intensity in most (X85%) cases. Few patients (o3%) received prophylactic breast irradiation or surgery for gynaecomastia and breast pain. The incidence of other adverse events was low in both treatment groups (Table 3) .
Withdrawals In Trial 24, withdrawal rates from randomised treatment were similar for bicalutamide and placebo (64.5 vs 69.0%). The withdrawal rates due to adverse events were greater for patients receiving bicalutamide than those receiving placebo (29.4 vs 10.9%); 17.8 and 0.9% withdrew due to gynaecomastia and/or breast pain, respectively. Fewer patients receiving bicalutamide withdrew due to objective progression than those receiving placebo (5 vs 14.5%, respectively). (Table 4 ) and no consistent pattern of nonprostate-cancer-related deaths was identified.
Discussion
Consistent with the earlier findings (at a median followup of 2.6 y), this second analysis of Trial 24 (at 5.1 y median follow-up) continues to show that the addition of bicalutamide 150 mg/day significantly improves objective and PSA PFS in patients who otherwise would not have received hormonal therapy following standard care. These differences were also observed irrespective of whether patients received adjuvant bicalutamide or would have otherwise undergone watchful waiting. There was no difference in overall survival in Trial 24 between bicalutamide and standard care alone. As Trial 24 is one of the three trials making up the EPC programme, it is important to consider these results in the context of the other two trials (Trials 23 and 25). The ongoing EPC programme comprises over 8000 men and the second analysis of this programme was conducted at a median follow-up of 5.4 y. This analysis demonstrated that, in patients receiving adjuvant therapy, long-term bicalutamide significantly improved objective PFS in those with locally advanced prostate cancer (T3-4, any N, M0 or any T, N þ , M0) disease, but not in those with localised (T1-2, N0 or Nx, M0) disease. 6 In those patients who underwent watchful waiting, the improvement was significant irrespective of disease stage, and most pronounced in patients with locally advanced disease. 6 An important finding from Trial 25 undertaken in Scandinavia, 7 where more than 80% of patients recruited underwent watchful waiting, was that the relative effect of bicalutamide on overall survival was dependent on disease stage. In patients with localised disease, survival appeared to be improved in those randomised to standard care alone and, conversely, survival appeared to favour bicalutamide therapy in patients with locally advanced disease.
In contrast to Trial 25, the statistical interaction test between randomised treatment and the prespecified baseline prognostic factors on overall survival in Trial 24 was not significant (P ¼ 0.57), suggesting that within Trial 24, baseline prognostic factors, such as disease stage, did not influence the relative effect of bicalutamide on overall survival. However, in light of the survival findings from Trial 25, it is important to investigate whether these trends were also seen in the watchful waiting patients of Trial 24 (there were no watchful waiting patients in Trial 23). In the watchful waiting subgroup of Trial 25, the HR for overall survival in patients with localised disease was 1.36 (95% CI 0.97, 1.91; P ¼ 0.07) for bicalutamide compared with standard care alone, and in patients with locally advanced disease 6 provide the best estimate of the effect of bicalutamide.
The combined analysis of Trials 23, 24 and 25 showed that in the watchful waiting population there was a trend towards reduced survival with bicalutamide in patients with localised disease (HR 1.23; 95% CI 1.00, 1.50; P ¼ 0.05) and a trend towards improved survival with bicalutamide in patients with locally advanced disease (HR 1.04; 95% CI 0.81, 1.33; P ¼ 0.78). 6 The findings from the EPC programme overall suggest that bicalutamide provides advantages to patients with locally advanced disease, while long-term early or adjuvant hormonal therapy for patients with localised disease is not appropriate in light of the current data.
Bicalutamide, therefore, significantly reduces the risk of disease progression in patients with locally advanced disease. The clinical relevance of this has been shown in a recent Medical Research Council study in the United Kingdom involving 938 patients with locally advanced or asymptomatic metastatic prostate cancer. This study reported that immediate hormonal therapy was associated with lower incidences of spinal cord compression, pathological fractures, ureteric obstruction and the development of extraskeletal metastases, compared with deferred treatment. 9 Furthermore, preventing or delaying disease progression is likely to have quality-of-life benefits for patients, and their families, as many experience physical, social and psychological problems at signs of advancing disease.
2,3,10,11 PSA and metastatic progression also pose a significant additional economic burden 4 and delaying disease progression with antiandrogen therapy can delay and reduce both the costs and suffering associated with advancing disease. 12 The benefits of adding hormonal therapy to standard care in patients with locally advanced prostate cancer are further supported by previous findings of other randomised trials with castration-based therapy. [13] [14] [15] Medical and surgical castration, however, can often be associated with adverse events such as decreased libido, sexual dysfunction, fatigue and vasodilation (hot flushes). 16 Furthermore, long-term therapy is associated with loss of bone mineral density, which can lead to osteoporotic fractures. [17] [18] [19] Data from two open-label, multicentre studies (studies 306 and 307), which were prospectively designed for pooled analysis, have demonstrated that in patients with locally advanced prostate cancer requiring immediate hormonal therapy, bicalutamide is similar to castration in terms of objective PFS and overall survival. 16 Studies 306 and 307 also demonstrated significant advantages in favour of bicalutamide in terms of maintaining sexual interest and physical capacity. 16 Other randomised trials indicate that in contrast to castration, bicalutamide preserves bone mineral density. 18, 19 In Trial 24, bicalutamide was associated with low incidences of decreased libido, impotence and hot flushes. The most common adverse events of bicalutamide treatment in Trial 24 were gynaecomastia and breast pain, which were of mild to moderate intensity in the majority of cases. Withdrawal rates due to these events were relatively low, suggesting that many patients are prepared to tolerate these symptoms given the improvements in objective and PSA PFS. However, there are also various prophylactic and therapeutic strategies available for the management of gynaecomastia and breast pain, including tamoxifen 20, 21 and breast irradiation. 22, 23 There is a potential concern that patients with early prostate cancer who show evidence of disease progression following first-line antiandrogen monotherapy will not respond to subsequent hormonal manipulation. However, recent evidence from a subset of patients within the EPC programme, reveals that approximately 55% of those who progressed on bicalutamide showed a PSA response (defined as a reduction in PSA X20% at X3 months post initiation of second-line therapy) to second-line hormonal therapy, mostly castration-based therapies. 24 Furthermore, the response rate for those patients who had objective progression did not differ from that of the patients who commenced second-line therapy for PSA progression. This suggests that patients who progress on bicalutamide may also respond to subsequent treatment with castration.
Conclusions
Consistent with the second analysis of the EPC programme as a whole, 6 the results of Trial 24, conducted at a median follow-up of 5.1 y, demonstrate that bicalutamide 150 mg/day following standard care significantly improved objective and PSA PFS in the overall Trial 24 population. No significant difference in overall survival was observed between bicalutamide and standard care within this study at the time of the analysis. Altogether, the results from the EPC programme suggest that based on the current evidence, long-term use of bicalutamide is not appropriate in patients with localised (T1-2, N0 or Nx, M0) disease, yet provides advantages in delaying disease progression in patients with locally advanced (T3-4, any N, M0 or any T, N þ , M0) disease. The EPC programme is ongoing and continued follow-up will provide further valuable information on the role of bicalutamide in the management of prostate cancer.
